Previous 10 | Next 10 |
PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on ultrasound-guide...
Pacira BioSciences (NASDAQ: PCRX ) has reported preliminary Q4 and FY 2019 net revenues. More news on: Pacira BioSciences, Inc., Healthcare stocks news, Read more ...
PARSIPPANY, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net revenue of $421.0 million for 2019, a 25% increase compared with net revenue of $337.3 m...
PARSIPPANY, N.J., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 38 th Annual J.P. Morgan Healthcare Conference at 9:30 AM PT (12:30 PM ET) on Wednesday, January 15, 2020. Live audio of the event can be accessed by v...
A Phase 4 study evaluating Pacira BioSciences's ( PCRX +0.1% ) non-opioid pain med Exparel (bupivacaine liposome injectable suspension) in women undergoing Cesarean section achieved the primary endpoint of a statistically significant reduction in postsurgical opioid consumption while m...
PARSIPPANY, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that its Phase 4 study of EXPAREL ® (bupivacaine liposome injectable suspension) in patients undergoing Cesarean section (C-section) achieved its primary endpoint with a statist...
Pacira BioSciences ( PCRX ) announces positive results from its Phase 3 PLAY study of EXPAREL (bupivacaine liposome injectable suspension) administered as a single-dose infiltration in pediatric patients undergoing spinal or cardiac surgeries. The study enrolled 98 patients. More ne...
PARSIPPANY, N.J., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc . (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced positive results from its Phase 3 PLAY study of EXPAREL ® (bupivacaine liposome injectable suspension) ...
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking John Paulson’s Paulson & Co...
PARSIPPANY, N.J., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 31 st Annual Piper Jaffray Healthcare Conference at 9:30 AM on Tuesday, December 3, 2019. Live audio of the event can be accessed by visiting the ...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
2024-04-23 18:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-09 11:15:02 ET RBC Capital analyst issues UNDERPERFORM recommendation for PCRX on April 9, 2024 10:00AM ET. The previous analyst recommendation was Underperform. PCRX was trading at $28.44 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-04-09 11:15:02 ET Wedbush analyst issues BUY recommendation for PCRX on April 9, 2024 10:00AM ET. The previous analyst recommendation was Buy. PCRX was trading at $28.44 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...